MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the ...

ProQR ( ) just unveiled an announcement. ProQR Therapeutics announced significant advancements in their Axiomer RNA-editing platform during their 2024 Investor and Analyst Event.

Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.08, a high estimate of $13.00, ...

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ...

V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its ...

The oligonucleotides market has gained significant traction in recent years due to its critical role in molecular biology, genetics, and therapeutics. Oligonucleotides, short DNA or RNA molecules, are ...

Lepidopterans (butterflies and moths) exhibit a splendid diversity of wing color patterns, and many species display black and ...

MGX-001 bioengineered FVIII construct exhibited higher FVIII activity at similar integration rates compared to wild type FVIII construct in preclinical studies; program on track for IND filing in 2026 ...

Recent research published in the journal “Science Bulletin” detailed the creation of a tool called ChCas12b that can ...

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell ...

In molecular biology, RNA modifications were traditionally associated with static structural components like rRNAs and tRNAs. However, advancements such as antibody immunoprecipitation and ...